These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18656557)

  • 1. Enhanced immunogenicity of a bivalent nicotine vaccine.
    Keyler DE; Roiko SA; Earley CA; Murtaugh MP; Pentel PR
    Int Immunopharmacol; 2008 Nov; 8(11):1589-94. PubMed ID: 18656557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions.
    Cornish KE; de Villiers SH; Pravetoni M; Pentel PR
    PLoS One; 2013; 8(12):e82557. PubMed ID: 24312662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.
    Pravetoni M; Keyler DE; Pidaparthi RR; Carroll FI; Runyon SP; Murtaugh MP; Earley CA; Pentel PR
    Biochem Pharmacol; 2012 Feb; 83(4):543-50. PubMed ID: 22100986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.
    Cornish KE; Harris AC; LeSage MG; Keyler DE; Burroughs D; Earley C; Pentel PR
    Int Immunopharmacol; 2011 Nov; 11(11):1809-15. PubMed ID: 21802529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.
    de Villiers SH; Cornish KE; Troska AJ; Pravetoni M; Pentel PR
    Vaccine; 2013 Dec; 31(52):6185-93. PubMed ID: 24176492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New directions in nicotine vaccine design and use.
    Pentel PR; LeSage MG
    Adv Pharmacol; 2014; 69():553-80. PubMed ID: 24484987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunization alters the plasma nicotine concentration in rats.
    Hieda Y; Keyler DE; Vandevoort JT; Kane JK; Ross CA; Raphael DE; Niedbalas RS; Pentel PR
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1076-81. PubMed ID: 9399979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats.
    Roiko SA; Harris AC; Keyler DE; Lesage MG; Zhang Y; Pentel PR
    J Pharmacol Exp Ther; 2008 Jun; 325(3):985-93. PubMed ID: 18305013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats.
    Pravetoni M; Raleigh MD; Le Naour M; Tucker AM; Harmon TM; Jones JM; Birnbaum AK; Portoghese PS; Pentel PR
    Vaccine; 2012 Jun; 30(31):4617-24. PubMed ID: 22583811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
    Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
    Front Immunol; 2019; 10():2497. PubMed ID: 31708925
    [No Abstract]   [Full Text] [Related]  

  • 11. Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins.
    Zhao Z; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C
    Nanomedicine; 2018 Jul; 14(5):1655-1665. PubMed ID: 29719216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the protective effects of a conformationally constrained nicotine vaccine.
    Moreno AY; Azar MR; Koob GF; Janda KD
    Vaccine; 2012 Oct; 30(47):6665-70. PubMed ID: 22963803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.
    Wagena EJ; de Vos A; Horwith G; van Schayck CP
    Nicotine Tob Res; 2008 Jan; 10(1):213-8. PubMed ID: 18188762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.
    Hu Y; Smith D; Frazier E; Hoerle R; Ehrich M; Zhang C
    Biomaterials; 2016 Nov; 106():228-39. PubMed ID: 27569868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.
    Laudenbach M; Tucker AM; Runyon SP; Carroll FI; Pravetoni M
    Vaccine; 2015 Nov; 33(46):6332-9. PubMed ID: 26409811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial.
    Hoogsteder PH; Kotz D; van Spiegel PI; Viechtbauer W; van Schayck OC
    Addiction; 2014 Aug; 109(8):1252-9. PubMed ID: 24894625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.
    Hatsukami DK; Jorenby DE; Gonzales D; Rigotti NA; Glover ED; Oncken CA; Tashkin DP; Reus VI; Akhavain RC; Fahim RE; Kessler PD; Niknian M; Kalnik MW; Rennard SI
    Clin Pharmacol Ther; 2011 Mar; 89(3):392-9. PubMed ID: 21270788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
    May RJ; Beenhouwer DO; Scharff MD
    J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.